• ipharmaservices

Lundbeck acquired Abide Therapeutics and their lead compound ABX-1431

Updated: Jun 3, 2019

Lundbeck has completed the acquisition of US-based biotech company Abide Therapeutics and the lead compound ABX-1431.

On May 6th, 2019 Lundbeck announced that it was acquiring Abide Therapeutics. Abide Therapeutics is currently working the serine hydrolases; the acquisition helps

Lundbeck to work on new classes of drugs for a range of therapeutic activities.

Also, Lundbeck gets the advanced compound ABX-1431 first-in-class MAG Lipase inhibitor used for the treatment of Tourette Syndrome and neuropathic pain.


Recent Posts

See All

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices